特此公告。 创业慧康科技股份有限公司 董事会 证券代码：300451 证券简称：创业慧康 公告编号：2025-059 创业慧康科技股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）于 2025 年 9 月 29 日、2025 年 10 月 15 日分别召开了第八届董事会第十九次会议和 2025 年第一次临时股东 大会，审议通过了《关于修改<公司章程>并办理工商变更登记备案的议案》， 对《公司章程》的部分条款进行修改和完善，根据修订后的《公司章程》，不设 监事会或者监事，由董事会审计委员会行使《公司法》规定的监事会职权，公司 第八届监事会监事将不再担任公司监事及履行监事职责。同时，公司根据修订后 的《公司章程》将新增 1 名职工代表董事，并由公司职工代表大会选举产生。 根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及 《公司章程》等有关规定，公司于 2025 年 10 月 17 日召开职工代 ...

Core Viewpoint - The stock of Chuangye Huikang (300451) has experienced a decline, with significant net outflows from major funds, indicating potential concerns about its financial performance and market sentiment [1][2]. Financial Performance - As of the latest report, Chuangye Huikang's total market value is 7.064 billion yuan, with a net asset value of 4.407 billion yuan [3]. - The company reported a net profit of -80.55 million yuan, reflecting a year-on-year decline of 394.25% [3]. - The main revenue for the first half of 2025 was 577 million yuan, down 20.65% year-on-year [3]. - The gross profit margin stands at 51.45%, which is higher than the industry average of 44.5% [3]. Stock Performance and Market Sentiment - On October 16, 2025, the stock closed at 4.56 yuan, down 2.15%, with a trading volume of 284,000 hands and a total transaction amount of 130 million yuan [1]. - Over the past five days, the stock has seen fluctuations in fund flows, with a notable net outflow of 10.26 million yuan from major funds on October 16 [2]. - The average target price set by institutions over the past 90 days is 6.37 yuan, with three institutions giving a buy rating [4]. Industry Comparison - Chuangye Huikang's price-to-earnings ratio (P/E) is -43.85, significantly lower than the industry average of 84.12 [3]. - The company ranks 166th in net profit within the software development industry, indicating challenges in profitability compared to peers [3].

Core Viewpoint - The stock of Chuangye Huikang has experienced a decline in recent trading sessions, with a notable drop in both stock price and trading volume, indicating potential concerns among investors [1][2]. Group 1: Stock Performance - As of October 16, Chuangye Huikang's stock price fell by 2.15% to 4.56 CNY per share, with a trading volume of 55.31 million CNY and a turnover rate of 0.79%, resulting in a total market capitalization of 7.064 billion CNY [1]. - Year-to-date, the stock has increased by 1.79%, but it has seen a decline of 5.98% over the last five trading days, 9.88% over the last twenty days, and 18.43% over the last sixty days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on March 10, where it recorded a net buy of -11.72 million CNY [1]. Group 2: Company Overview - Chuangye Huikang, established on December 10, 1997, and listed on May 14, 2015, is based in Hangzhou, Zhejiang Province, and specializes in healthcare information technology services [2]. - The company's main business segments include medical information application software (44.48%), technical services (44.95%), and system integration (9.59%) [2]. - As of September 10, the number of shareholders decreased by 10.27% to 64,800, while the average circulating shares per person increased by 11.45% to 23,547 shares [2]. Group 3: Financial Performance - For the first half of 2025, Chuangye Huikang reported a revenue of 577 million CNY, reflecting a year-on-year decrease of 20.65%, and a net profit attributable to shareholders of -80.55 million CNY, a significant decline of 394.25% [2]. - The company has distributed a total of 230 million CNY in dividends since its A-share listing, with 30.94 million CNY distributed over the past three years [3]. Group 4: Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders include Noan Active Return Mixed A, which holds 24.14 million shares, a decrease of 7.33 million shares from the previous period [3]. - Hong Kong Central Clearing Limited and Southern CSI 1000 ETF have also adjusted their holdings, with the former decreasing by 6.89 million shares and the latter increasing by 0.21 million shares [3].

北京市天元律师事务所 本所及经办律师同意将本法律意见作为本次股东大会公告的法定文件，随同其他 公告文件一并提交深圳证券交易所（以下简称"深交所"）予以审核公告，并依法对出 具的法律意见承担责任。 关于创业慧康科技股份有限公司 2025 年第一次临时股东大会的法律意见 京天股字（2025）第 641 号 致：创业慧康科技股份有限公司 创业慧康科技股份有限公司（以下简称"公司"）2025 年第一次临时股东大会 （以下简称"本次股东大会"）采取现场投票与网络投票相结合的方式召开，现场会 议于 2025 年 10 月 15 日（星期三）14:30 在杭州市滨江区浦沿街道坚塔街 708 号创 业慧康大厦三楼会议室召开。北京市天元律师事务所（以下简称"本所"）接受公司 聘任，指派本所律师参加本次股东大会现场会议，并根据《中华人民共和国公司法》 《中华人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》（以下 简称《股东会规则》）以及《创业慧康科技股份有限公司章程》（以下简称《公司章 程》）等有关规定，就本次股东大会的召集、召开程序、出席现场会议人员的资格、 召集人资格、会议表决程序及表决结果等事项出具本法律意 ...

为贯彻落实《中华人民共和国公司法》，进一步提升上市公司规范运作水平， 公司根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程 指引（2025 年修订）》《深圳证券交易所创业板股票上市规则（2025 年修订）》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作 （2025 年修订）》等相关法律法规及规范性文件的规定，结合公司经营发展需 要，根据新修订的《公司法》和《公司章程》的有关规定，公司董事会决定： （一）选举董事长张吕峥为代表公司执行公司事务的董事，并担任公司的 法定代表人。任期自本次董事会审议通过之日起至本届董事会任期届满之日止。 本次选举后，公司法定代表人未发生变更。 （二）确认公司第八届董事会审计委员会仍由谭青女士（独立董事）、蔡家 楣先生（独立董事）、应晶先生三位董事组成，审计委员会成员中独立董事占多 数，并由会计专业人士谭青女士担任召集人。任期自本次董事会审议通过之日 第八届董事会第二十次会议决议的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"或"本公司"）第八 ...

本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无新增、变更、否决提案的情况； 2、本次股东大会不涉及变更前次股东大会的决议； 3、本次股东大会以现场投票和网络投票相结合的方式召开； 4、为尊重中小投资者利益，提高中小投资者对本次股东大会决议事项的参 与度，本次股东大会对审议影响中小投资者利益的重大事项进行单独计票。中小 投资者是指除上市公司董事、监事、高级管理人员以及单独或者合计持有公司 5%以上股份的股东以外的其他股东。 一、会议召开和出席情况 证券代码：300451 证券简称：创业慧康 公告编号：2025-057 创业慧康科技股份有限公司 2025年第一次临时股东大会决议公告 （一）会议召开情况 1、召开时间： （1）现场会议日期和时间：2025 年 10 月 15 日（星期三）下午 14:30 （2）网络投票日期和时间：2025 年 10 月 15 日。其中，通过深圳证券交易 所交易系统进行网络投票的具体时间为：2025年10月15日9:15-9:25、9:30-11:30， 13:00-15:00。通过深圳证券交易所互联网投票 ...

Summary of Key Points Core Viewpoint - Several companies are experiencing significant shareholder reductions, with multiple stakeholders planning to decrease their holdings by various percentages, indicating potential shifts in investor confidence and market dynamics [1]. Shareholder Reductions - Watson Pharmaceutical's controlling shareholder plans to reduce holdings by up to 3% [1] - Tianli Lithium Energy's New Materials Fund intends to reduce holdings by up to 3% [1] - Guangkang Biochemical's shareholder Ruihong Kaiyin No.1 plans to reduce holdings by up to 2.6757% [1] - Huayi Technology's shareholder Huang Daqing aims to reduce holdings by no more than 3% [1] - Magu Technology's shareholder Xu Longxiang plans to reduce holdings by up to 0.86% [1] - Saiwu Technology's shareholders Suzhou Suyu and Suzhou Saiying plan to collectively reduce holdings by 1.32% [1] - New Xunda's Minmetals International Trust has cumulatively reduced holdings by 1% [1] - Yandong Micro's Jingguorui has cumulatively reduced 1% of company shares [1] - Aohua Endoscopy's shareholders Junlian Xinkang and Gao Shen have cumulatively reduced 1.92% of shares [1] - Zhejiang Natural's Tiantai Ruiju Equity Investment Center has completed a 1% reduction in company shares [1] - Chunzong Technology's He Shida has cumulatively reduced 2 million shares [1] - Chiao Sensor's Li Hongqing has reduced 16 million shares through block trading [1] - Chuangye Huikang's Philips has cumulatively reduced 1.0195% of shares [1] Other Notable Events - Ruyi Group is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] - Huangting International has terminated plans for significant asset sales and debt restructuring [1]

格隆汇10月14日丨创业慧康(300451.SZ)公布，近日收到飞利浦（中国）投资有限公司（简称"飞利浦"） 出具的《告知函》，飞利浦已通过集中竞价及大宗交易方式合计减持公司股份15,793,764股，占公司总 股本1.019528%（占剔除公司回购专用账户股份后的总股本比例为1.022630%）。 ...

每经AI快讯，10月14日，创业慧康（300451）(300451.SZ)公告称，公司收到飞利浦(中国)投资有限公司 出具的《告知函》，飞利浦于2025年9月25日至2025年10月10日通过集中竞价及大宗交易方式合计减持 公司股份约1579万股，占公司总股本1.019528%，所持公司股份比例从9.999996%下降至8.977366%。本 次权益变动不会导致公司控制权发生变更，不会对公司治理结构及持续经营产生重大影响。 ...

创业慧康(300451.SZ)公告称，公司收到飞利浦（中国）投资有限公司出具的《告知函》，飞利浦于 2025年9月25日至2025年10月10日通过集中竞价及大宗交易方式合计减持公司股份1579万股，所持公司 股份比例从9.999996%下降至8.977366%，占公司总股本1.019528%。本次权益变动不会导致公司控制权 发生变更，不会对公司治理结构及持续经营产生重大影响。 ...